Programmed Cell Death News and Research

RSS

New funding supports LMU research on pediatric inflammatory bowel disease

The non-profit Boehringer Ingelheim Stiftung supports LMU clinician-scientist Daniel Kotlarz through its Rise up! program.

10 Sep 2026

Tumor environments sculpt diverse natural killer cells for cancer therapies

For decades, natural killer (NK) cells have been classified into two main groups based on surface markers: one specialized for cytokine production and the other for direct killing.

4 Sep 2026

A striking immune cell pattern emerges around a person’s 100th birthday

Single-cell immune profiling found that CD4 cytotoxic T lymphocytes become more abundant around age 100, showing stepwise differentiation and substantial clonal expansion. Ex vivo experiments also revealed cytokine plasticity within individual clones, supporting the hypothesis that these cells adapt to persistent antigens during healthy aging, although their direct role in longevity remains unproven.

23 Aug 2026

Glioma microenvironment emerges as key target for future therapies

The prognosis for glioma patients remains extremely poor despite aggressive multimodal standard therapy: maximal safe resection, radiotherapy, and temozolomide chemotherapy, with median survival rarely exceeding 15 to 18 months.

20 Aug 2026

HMGCR emerges as a promising target for precision cancer therapies

A growing body of evidence is reshaping how scientists and clinicians understand the role of cancer metabolism, placing the enzyme HMGCR at the center of a rapidly evolving therapeutic landscape.

5 Aug 2026

UCLA researchers find strategy to improve prostate cancer therapies

UCLA researchers have identified a promising strategy to make a new class of targeted cancer therapies more effective against one of the deadliest forms of prostate cancer, potentially overcoming treatment resistance that has limited their success.

3 Aug 2026

Dual immunotherapy with neoadjuvant chemotherapy shows encouraging activity in ERBB2-negative breast cancer

A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given prior to surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to phase 2 clinical trial results from the ongoing I-SPY2 clinical trial platform.

30 Jul 2026

Two interconnected signaling pathways drive papillary thyroid carcinoma progression

A new research perspective was published in Volume 13 of Oncoscience on June 3, 2026, titled "The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma."

24 Jul 2026

Cell death crosstalk network drives acute respiratory distress syndrome

Acute respiratory distress syndrome (ARDS) remains one of the deadliest complications of severe infections, sepsis, trauma, and viral pneumonia, yet decades of research have produced few targeted therapies capable of improving patient outcomes.

14 Jul 2026

Structural study identifies unexpected cancer-regulating functions of MLL4 protein

The epigenetic modifier MLL4 has an unassuming name-the 4, for instance, indicates it's just one in a family of such modifiers.

13 Jul 2026

Evolutionary noncoding RNAs reveal new targets for cancer therapy

In cancer research, one person's junk is increasingly becoming another person's treasure. Scientists have now uncovered new evidence showing how recently evolved "junk DNA" genetic elements can become integrated into ancient cellular pathways that regulate cancer.

1 Jul 2026

New AI framework outperforms conventional biomarkers in predicting cancer survival

Digestive system cancers, including hepatobiliary and gastrointestinal malignancies, remain a major global oncological burden. Although immune checkpoint inhibitors have changed the treatment landscape for some patients, their overall efficacy remains limited, with only about 15% to 30% of patients achieving durable clinical benefit.

1 Jul 2026

Brazilian researchers identify cell molecule that drives cancer progression

Researchers at the Federal University of São Paulo (UNIFESP) in Brazil have identified a molecule on the surface of cells that could be a promising therapeutic target against cancer.

18 Jun 2026

New DNA tetrahedron nanostructures improve targeted cancer therapy delivery

Conventional cancer treatments, such as chemotherapy, often lack specificity and can damage both cancerous and healthy cells, leading to severe side effects.

10 Jun 2026

New study frames altered protein modifications as cancer drivers

Cancer has often been explained through mutations in deoxyribonucleic acid (DNA) or changes in ribonucleic acid (RNA), but these layers do not fully explain why tumors with similar genetic profiles can behave differently.

9 Jun 2026

AI-designed molecular switch uses caffeine to control engineered cells

For many of us, a warm cup of coffee is how we start our day. For Texas A&M Health researchers, it may also offer a new way to control engineered cells in future medicines.

8 Jun 2026

Study shows how TAF1 regulates ferroptosis in cancer cells

Ferroptosis has become a promising area in cancer research because it may provide a way to target tumor cells that evade other better-known forms of programmed cell death, such as apoptosis and necroptosis.

3 Jun 2026

Researchers find new way to deliver drugs directly into cancer cells

National University of Singapore Researchers at the National University of Singapore (NUS) have developed a high-throughput method to identify gold nanoparticles capable of delivering therapies directly to mitochondria (the energy centres inside cancer cells).

13 May 2026

Timing of trauma strongly influences adult brain function and behavior

A research team from the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology), in collaboration with the IRCCS Istituto Giannina Gaslini in Genoa (Italy), has demonstrated that traumatic experiences occurring at specific stages of life - particularly from childhood through the early years following adolescence - have persistent effects on brain development and adult behavior.

12 May 2026

Diverse leukemia stem cells may drive AML relapse after therapy

Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in acute myeloid leukemia (AML).

7 May 2026